Chronic Lymphocytic Leukemia Clinical Trial
Official title:
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC). The purpose of this study is to determine the response rate of the combination of Revlimid® and Rituximab in previously untreated CLL patients in two arms- those aged 65 years and above and those younger than 65. Secondary objectives will evaluate the safety of the combination of Revlimid® and Rituximab, response duration, improvement in hematologic parameters, and the significance of the tumor flare reaction. All patients will have assessment of known prognostic factors for CLL as well as novel prognostic factors will be evaluated for predicting response to treatment. Biologic corollary studies are designed to evaluate the mechanism of Revlimid® in CLL and the combination of Revlimid® and Rituximab.
The CLL Research Consortium (CRC) is conducting a two-arm, multi-center phase II trial of
Revlimid® and rituximab for the first-line treatment of patients with CLL.
Revlimid® (lenalidomide) a derivative of thalidomide with immune-modulating properties.
Revlimid® is FDA approved for treatment of relapsed multiple myeloma and 5q- myelodysplastic
syndrome. Revlimid® has promising clinical activity in relapsed CLL in two early clinical
trials. However, the mechanism(s) whereby Revlimid® is active in CLL is unknown. Rituximab
(Rituxan®) is a protein that binds to CD20 expressed on normal and leukemia B cells.
Rituximab is FDA approved for the treatment of lymphoma and is used commonly for the
treatment of CLL. The purposes of this study are to evaluate the safety and activity of the
combination of Revlimid® and rituximab in CLL, elucidate the mechanism of Revlimid® in CLL,
and to assess whether prognostic factors might predict those patients likely to benefit from
this therapy in the future.
As older patients are commonly under-represented in CLL clinical trials and are less
tolerable of frontline therapy that utilizes combinations of fludarabine and
cyclophosphamide the trial has two arms; one to specifically assess for the tolerability of
the regimen in older subjects.
The primary objective of this study is to determine the response rate of the combination of
Revlimid® and Rituximab in previously untreated CLL patients in two arms- those aged 65
years and above and those younger than 65. Secondary objectives will evaluate the safety of
the combination of Revlimid® and Rituximab, response duration, improvement in hematologic
parameters, activity of the combination in high-risk CLL subsets, and the significance of
the tumor flare reaction.
All patients will have baseline assessment of known CLL prognostic factors including:
immunoglobulin variable heavy chain (IgVH) gene mutational status, interphase cytogenetics,
intracellular ZAP-70 expression, and CD38 expression through the CRC tissue core. These
known prognostic features in CLL together with novel prognostic factors will be evaluated
for the ability to predict response to treatment with Revlimid® and the combination of
Revlimid® and Rituximab. Extensive biologic corollary studies are designed to evaluate the
mechanism of Revlimid® in CLL, the impact of Revlimid® on the CLL microenvironment, and
Revlimid®'s impact on and rituximab mediated cytotoxicity.
All patients will receive the same treatment. Revlimid® will be started at a low dose and
slowly escalated based on patient tolerability. Rituximab will be administered following 21
days of Revlimid® monotherapy. Patients will continue treatment for up to 7 cycles unless
there is toxicity or progressive disease. There are three planned response assessments for
the subjects: a single agent Revlimid® response assessment prior to the addition of
rituximab, after 3 cycles of treatment, and following all the therapy.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
| Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
| Active, not recruiting |
NCT04240704 -
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
|
Phase 1 | |
| Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03280160 -
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
|
Phase 2 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
| Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
| Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
| Recruiting |
NCT05417165 -
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT04028531 -
Understanding Chronic Lymphocytic Leukemia
|
||
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
| Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
| Recruiting |
NCT04679012 -
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
|
Phase 2 | |
| Recruiting |
NCT05405309 -
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05023980 -
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
| Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
| Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|